Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
GAITHERSBURG, Md., April 13, 2016 -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the FBR Healthcare Series Conference New Prescriptions: Innovation in the Treatment of Diseases and Infections.
Conference details are as follows:
Date: Wednesday, April 20, 2016
Time: 9:30 a.m. U.S. Eastern Time
Location: J.W. Marriott Essex House, New York City
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
